Personalized versus evidence-based medicine with PET-based imaging
- PMID: 20700107
- DOI: 10.1038/nrclinonc.2010.121
Personalized versus evidence-based medicine with PET-based imaging
Abstract
In this Perspective the feasibility, scope and impact of integrating PET-based personalized medicine into the evidence-based clinical practice of oncology is discussed. The basic concepts of 'evidence-based medicine' and 'personalized medicine' at times seem contradictory; however, I will discuss, with specific clinical situations as examples, a synergistic and probably incremental link between the two and propose that the result of such integration will ultimately improve patient management. Tailoring therapeutic approaches and regimens by molecular imaging, with PET at its forefront, would enable disease management at the individual level and this modification would hopefully further strengthen the evidence-based approach in oncology.
Similar articles
-
The role of 18F-FDG PET in oncology: clinical and resource implications.Nucl Med Rev Cent East Eur. 2006;9(1):1-5. Nucl Med Rev Cent East Eur. 2006. PMID: 16791796 Review. No abstract available.
-
PET-Based Personalized Management in Clinical Oncology: An Unavoidable Path for the Foreseeable Future.PET Clin. 2016 Jul;11(3):203-7. doi: 10.1016/j.cpet.2016.03.002. Epub 2016 May 2. PET Clin. 2016. PMID: 27321025 Review.
-
18F-FDG PET/CT imaging in oncology.Ann Saudi Med. 2011 Jan-Feb;31(1):3-13. doi: 10.4103/0256-4947.75771. Ann Saudi Med. 2011. PMID: 21245592 Free PMC article. Review.
-
Imaging of Tumor Metabolism Using Positron Emission Tomography (PET).Recent Results Cancer Res. 2016;207:177-205. doi: 10.1007/978-3-319-42118-6_8. Recent Results Cancer Res. 2016. PMID: 27557539 Review.
-
Clinical applications of positron emission tomography in sarcoma management.Expert Rev Anticancer Ther. 2011 Feb;11(2):195-204. doi: 10.1586/era.10.133. Expert Rev Anticancer Ther. 2011. PMID: 21342039 Review.
Cited by
-
Nuclear medicine, scientific publishing and the era of cost containment: what factors hold the key?Eur J Nucl Med Mol Imaging. 2012 Aug;39(8):1358-9. doi: 10.1007/s00259-012-2111-2. Epub 2012 Apr 14. Eur J Nucl Med Mol Imaging. 2012. PMID: 22526954 No abstract available.
-
(99m)Tc-Annexin A5 quantification of apoptotic tumor response: a systematic review and meta-analysis of clinical imaging trials.Eur J Nucl Med Mol Imaging. 2015 Dec;42(13):2083-97. doi: 10.1007/s00259-015-3152-0. Epub 2015 Aug 16. Eur J Nucl Med Mol Imaging. 2015. PMID: 26275392
-
Assessment of the biodistribution of an [(18) F]FDG-loaded perfluorocarbon double emulsion using dynamic micro-PET in rats.Contrast Media Mol Imaging. 2013 Jul-Aug;8(4):366-74. doi: 10.1002/cmmi.1532. Contrast Media Mol Imaging. 2013. PMID: 23613440 Free PMC article.
-
Role of 18F-fluorodeoxyglucose (FDG) and 18F-2-fluorodeoxy sorbitol (FDS) in autoimmune hypophysitis: a case report.BMC Endocr Disord. 2020 Jun 9;20(1):84. doi: 10.1186/s12902-020-00567-8. BMC Endocr Disord. 2020. PMID: 32517690 Free PMC article.
-
Positron emission tomography image-guided drug delivery: current status and future perspectives.Mol Pharm. 2014 Nov 3;11(11):3777-97. doi: 10.1021/mp500173s. Epub 2014 Jun 4. Mol Pharm. 2014. PMID: 24865108 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources